Medicamental correction of pathomorphological changes of the ocular surface in patients with steroid therapy intolerance after photorefractive keratectomy (in Russian only)

Close metadata

Introduction. The problems of controlling inflammatory and proliferative response of the retina and correcting tear production in the post-operative period after photorefractive keratectomy (PRK) have not been fully solved yet. Patients intolerable to local steroids require an alternative. One drug that covers those needs is Cyclosporine 0.05%. Purpose — to analyze clinical effectiveness of Restasis eye drops in solving inflammatory-degenerative response and tear production insufficiency (dry eye syndrome) for post-PRK patients with steroid eye drops intolerance accompanied with increasing intraocular pressure (IOP). Patients and methods. Retrospective analysis of 14 myopic patients (28 eyes) was conducted; mean patient age was 25.9±6 years; myopia was (–)5.65±1.5 Diopters of spherical equivalent (SE); corneal-compensated IOP was 16.98±3.68 mm Hg before the surgery. All patients underwent excimer laser correction (PRK or Trans-PRK) with Schwind Amaris (SCHWIND eye-tech-solutions). After epithelization, all patients were prescribed 0.1% Dexamethasone solution 4 times a day (with decreasing dosing frequency) for 2 months, as well as local lubricants. The article also describes a separate clinical case of subepithelial fibroplasia that occurred post-PRK and was successfully stopped. Results. All patients had transitory IOP increase caused by local steroid therapy. Mean IOP at 1-month post-op was 20.5±7 mm Hg. At that point local steroids were replaced with 'Restasis' 0.05% (Cyclosporine) eye drops prescribed 2 times per day for 2 months. As the result, IOP values decreased to 16.2±3.21 mm Hg (without any additional therapy); at 6 months mean uncorrected visual acuity reached 0.98±0.05, best corrected visual acuity achieved 1.03±0.06 and SE was 0.04±0.12 Diopters. Conclusion. Local Cyclosporine ('Restasis') is the method of choice for regulation of inflammatory and degenerative response and tear production insufficiency (dry eye syndrome) for post-PRK patients with intolerance to steroid eye drops.

Keywords:

PRK

Trans-PRK

Cyclosporine

surface ablation

dry eye

proliferative response

inflammatory response

ocular hypertension

tear production

Authors:

skina .N.

OOO "Klinika lazernoĭ meditsiny "Sfera" professora skinoĭ"

Maychuk N.V.

S. Fyodorov Eye Microsurgery Federal State Institution, 59A Beskudnikovsky Blvd., Moscow, Russian Federation, 127486

Parshina V.A.

Ophthalmology Clinic 'Sphere', 10 Starokachalovskaya St., Moscow, Russian Federation, 117628

Kukleva O.Y.

Ophthalmology Clinic 'Sphere', 10 Starokachalovskaya St., Moscow, Russian Federation, 117628

List of references:

Puliafito CA, Steinert RF, Deutsch TF, Hillenkamp F, Dehm EJ, Adler CM. Excimer laser ablation of the cornea and lens. Experimental studies. Ophtalmology. 1985;92(6):741-748.
Salz JJ, Maguen E, Macy JI, Papaioannou T, Hofbauer J, Nesburn AB. One-year results of excimer laser photorefractive keratectomy for myopia. Refract Corneal Surg. 1992;8(4):269-273.
Brancato R, Tavola A, Carones F, Scialdone A, Gallus G, Garancini P, Fontanella G. Excimer laser photorefractive keratectomy for myopia: results in 1165 eyes. Italian Study Group. Refract Corneal Surg. 1993;9(2):95-104.
Seiler T, Holschbach A, Derse M, Jean B, Genth U. Complications of myopic photorefractive keratectomy with the excimer laser. Ophthalmology. 1994;101(1):153-160.
Doga V, Kishkin YuI, Maychuk NV, Branchevskaya ES. Topography-guided PRK — the method of choice in high induced irregularity of the ocular surface correction. Oftal’mokhirurgiya. 2012;3:8-11. (In Russ.)
Netto MV, Mohan RR, Ambrósio R Jr, Hutcheon AE, Zieske JD, Wilson SE. Wound healing in the cornea: a review of refractive surgery complications and new prospects for therapy. Cornea. 2005;24(5):509-522.
Eskina EN, Parshina VA, Stepanova MA. Rezul’taty korrektsii miopii vysokoi stepeni metodom transepitelial’noi FRK na ustanovke SCHWIND AMARIS. Sovremennye tekhnologii v oftal’mologii. 2014;3:239-243. (In Russ.)
Eskina EN, Parshina VA, Stepanova MA. The experience of Tregaloza based lubricant usage for patients who underwent excimer laser surgery. Oftal’mologiya. 2016;13(3):213-218. (In Russ.) https://doi.org/10.18008/1816-5095-2016-3-213-218
Erie JC. Corneal wound healing after photorefractive keratectomy: a 3-year confocal microscopy study. Transactions of the American Ophthalmological Society. 2003;101:293-333.
Jester JV, Petroll WM, Cavanagh HD. Corneal stromal wound healing in refractive surgery: the role of myofibroblasts. Progress in Retinal and Eye Research. 1999;18(3):311-356. https://doi.org/10.1016/S1350-9462(98)00021-4
Møller-Pedersen T, Cavanagh HD, Petroll WM, Jester JV. Stromal wound healing explains refractive instability and haze development after photorefractive keratectomy: a 1-year confocal microscopic study. Ophthalmology. 2000;107(7):1235-1245. https://doi.org/10.1016/S0161-6420(00)00142-1
Jester JV. Corneal crystallins and the development of cellular transparency. Seminars in Cell & Developmental Biology. 2008;19(2):82-93. https://doi.org/10.1016/j.semcdb.2007.09.015
Barbosa FL, Chaurasia SS, Kaur H, de Medeiros FW, Agrawal V, Wilson SE. Stromal interleukin-1 expression in the cornea after haze-associated injury. Experimental Eye Research. 2010;91(3):456-461. https://doi.org/10.1016/j.exer.2010.06.023
Kaur H, Chaurasia SS, Agrawal V, Suto C, Wilson SE. Corneal myofibroblast viability: Opposing effects of IL-1 and TGF β1. Experimental Eye Research. 2009;89(2):152-158. https://doi.org/10.1016/j.exer.2009.03.001
Møller-Pedersen T, Petroll WM, Cavanagh HD, Jester JV. Neutralizing antibody to TGFbeta modulates stromal fibrosis but not regression of photoablative effect following PRK. Current Eye Research. 1998;17(7):736-747.
McGhee CNJ, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Safety. 2002;25(1):33-55. https://doi.org/10.2165/00002018-200225010-00004
Fagerholm P, Hamberg-Nyström H, Tengroth B, Epstein D. Effect of postoperative steroids on the refractive outcome of photorefractive keratectomy for myopia with the Summit excimer laser. Journal of Cataract and Refractive Surgery. 1994;20(1):212-215. https://doi.org/10.1016/S0886-3350(13)80755-9
Gartry DS, Muir MG, Lohmann CP, Marshall J. The effect of topical corticosteroids on refractive outcome and corneal haze after photorefractive keratectomy. A prospective, randomized, double-blind trial. Archives of Ophthalmology. 1992;110(7):944-952. https://doi.org/10.1001/archopht.1992.01080190050028
Vetrugno M, Maino A, Cardia G, Quaranta GM, Cardia L. A randomised, double masked, clinical trial of high dose vitamin A and vitamin E supplementation after photorefractive keratectomy. British Journal of Ophthalmology. 2001;85(5):537-539.
Girard B. Corticosteroids and ophthalmology. La Revue du praticien. 1990;40(6):536-540. (In French).
Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta ophtalmologica Scandinavica. 2005;83(6):645-663. https://doi.org/10.1111/j.1600-0420.2005.00592.x
Reichle ML. Complications of intravitreal steroid injections. Optometry. 2005;76(8):450-460. https://doi.org/10.1016/j.optm.2005.06.013
Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea. 2008;27:50-55. https://doi.org/10.1097/ICO.0b013e31815873c7
Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Survey of Ophthalmology. 2010;55(2):108-133. https://doi.org/10.1016/j.survophthal.2009.07.005
Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Survey of Ophthalmology. 2009;54(3):321-338. https://doi.org/10.1016/j.survophthal.2009.02.002
Maychuk DYu, Vasilyeva OA. Features of 0.05% cyclosporine (Restasis) application in treatment of recurrent infiltrative adenoviral keratitis. Oftal’mokhirurgiya. 2014;2:66-72. (In Russ.) https://doi.org/10.25276/0235-4160-2014-2-66-72
Schultz C. Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye. Ophthalmology and Eye Diseases. 2014;6:37-42. https://doi.org/10.4137%2FOED.S16067
Kaçmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Foster CS. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576-584. https://doi.org/10.1016/j.ophtha.2009.08.010
Shii D, Nakagawa S, Shinomiya K, Yoshimi M, Katsuta O, Oda T, Nakamura M. Cyclosporin A eye drops inhibit fibrosis and inflammatory cell infiltration in murine type I allergic conjunctivitis without affecting the early-phase reaction. Current Eye Research. 2009;34(6):426-437.
Nien CJ, Flynn KJ, Chang M, Brown D, Jester JV. Reducing peak corneal haze after photorefractive keratectomy in rabbits: Prednisolone acetate 1.00% versus cyclosporine A 0.05%. Journal of Cataract and Refractive Surgery. 2011;37(5):937-944. https://doi.org/10.1016/j.jcrs.2010.11.035
Gum SI, Kim YH, Jung JC, Kim IG, Lee JS, Lee KW, Park YJ. Cyclosporine A inhibits TGF-β2-induced myofibroblasts of primary cultured human pterygium fibroblasts. Biochemical and Biophysical Research Communications. 2017;482(4):1148-1153. https://https://doi.org/ 10.1016/j.bbrc.2016.12.002
Shchuko AG, Gorodetskii BK, Gorenskii AA, Bukina VV, Popova EG, Malyushev VV. Patogeneticheski obosnovannaya sistema reabilitatsionnykh meropriyatii v eksimerlazernoi khirurgii. Klinicheskaya oftal’mologiya. 2001;3:87. (In Russ.)

Close metadata